home       
   
 
 

Biotecnol leverages its business income by establishing in-house collaborative programmes.

Biotecnol uses its proprietary antibody engineering platforms, cell line development capabilities, upstream and downstream processing, analytics and QC experience for delivering GMP/GLP grade products and associated compliant processes for biomanufacturing for clinical trials.

Biotecnol has several internal development programmes in oncology and a strong client-based activity with established track-record.

Independently from what stage your company is at, Biotecnol could help you in developing a biologics-manufacturing strategy early in the drug-development process. 


For more information contact:

Dr. Phillip Cunnah, Director of Development & Manufacturing.
Email: pjc@biotecnol.com
 
Biotecnol has in-house capability for development of biopharmaceutical products up clinical stages. That includes scale-up and transfer of well characterised processes to cGMP facilities with whom Biotecnol has established collaborations over a decade.